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Abstract
Bacteriophages, or phages, are viruses that specifically infect and kill bacterial cells.
Phages are the most numerous biological entities on Earth, with an estimated population size of
1031 (1). Discovery, purification, and characterization of phages illuminate the composition of the
microbial world and provide potential applications in medicine. To combat antibiotic-resistant
bacteria, phages are being investigated as supplements or alternatives to antibiotics. Methicillinresistant Staphylococcus aureus (MRSA) is a commonly acquired infection in hospitals that has
become difficult to treat due to its resistance to antibiotics commonly used to treat ordinary S.
aureus infections (20). Bacteriophage, JB, isolated from dairy cow hair samples by Tyler
Nygaard at Montana State University, has the ability to infect MRSA USA300 strain
LAC. Genome annotation of this phage characterized it as a 42,683 bp circularly permuted
genome with 68 putative protein coding genes, and a G/C content of 35.2%. Through
bioinformatic analysis it was discovered that in a cluster of reverse transcribed (genes 3033), putative integrase and toxin genes were present (21). In order for this phage to be used
therapeutically in mammalian organisms, the deletion of these genes is essential to prevent the
possibility for the phage to produce viable lysogen bacterial cells with enhanced pathogenicity.
Genetic engineering to remove genes 30-33 was performed using type the type II CRISPR-Cas9
system to generate a strictly lytic deletion mutant JB bacteriophage, JBΔ30-33. The creation of
the lytic derivative of JB bacteriophage, JBΔ30-33, was confirmed by clear plaque morphology,
polymerase chain reaction, and DNA sequencing.
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Glossary of Terms
Term
Bacteriophage

Definition
A virus that infects and kills bacteria.

Lysogen

A bacterium harboring a bacteriophage genome within the bacterial
chromosome.

CRISPR-Cas9

A protein/RNA complex that creates double stranded breaks within a DNA
sequence of interest.

Toxin

A small molecule, peptide, or protein that is toxic when introduced to body
tissues by interaction with cellular receptors or enzymes.

Bacteriophage
Integrase

A site-specific recombinase that inserts a bacteriophage genome into a
bacterial chromosome.

Antibiotic
Resistance

Bacteria or other microorganisms’ that are resistant to antibiotic treatment.
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1. Background
1.1.

Bacteriophages

Bacteriophages, or phages, are viruses that specifically infect and kill bacterial cells.
Phages are the most numerous biological entities on Earth, with an estimated population size of
1031 (1). Phages were co-discovered by William Twort in 1915 and Felix d’Herelle in 1917 (2,3).
The genetic material of phages is composed of either DNA or RNA and may be doubleor single-stranded; however, a vast majority of characterized phages utilize dsDNA (4). Phage
genomes (nucleic acids) are densely packaged and encompassed by an icosahedral protein capsid
(4). From the small number of sequenced phage genomes collected, phages have been
determined to be billions of years old and genetically diverse (5). Phage genomic architectures
and sequences have distinct evolutionary histories and a mosaicism that suggests extensive
horizontal genetic transfer (6).
There are three virion morphologies of dsDNA phages: Myoviridae, contractile tails built
on a base plate; Podoviridae, very short tails; and Siphoviridae, long non-contractile tails (4).
Phages are prevalent in many environmental conditions and are an excellent model for genuine
scientific discovery; undergraduate students can generate hypotheses about uncharacterized
phages for research opportunities (7).
Some phages are strictly lytic while others are termed “temperate.” In the lytic cycle the
bacteriophage infects the host bacteria cell, uses the cell’s replication machinery to produce
progeny phage, and leaves the cell after cell lysis. There are five stages of the lytic cycle:
attachment, entry, phage replication DNA transcription/translation, assembly, and lysis.
Attachment of the phage occurs when the phage tail proteins bind to specific receptors on the
host cell’s surface. The bacteriophage injects its dsDNA into the cytoplasm of the host bacteria

2
cell. The host cell’s replication, transcription and translation machinery is forced to make copies
of the phage’s viral genome as well as viral proteins. Packaging of the viral genome into
assembled protein capsids produces progeny phage particles. To lyse the bacterium, phageencoded proteins that perforate the plasma membrane and the cell wall are expressed (8). Once
the cell is lysed, progeny phage are released and can infect nearby cells (figure 1).

Figure 1. Bacteriophage Lifecycles.
A diagram of the lytic and lysogenic lifecycles that bacteriophages can undergo (8).

A subset of phages, termed “temperate” can undergo both the lytic or the lysogenic
lifecycles. In the lysogenic cycle, once the bacteriophage DNA enters the host the cell the phage
DNA is recombined into the bacterial host’s chromosome (8). Integration of the phage genome
into the host bacterial chromosome occurs by phage-encoded integrase proteins. Integrase
proteins are site-specific recombinases that recognize short sequences of DNA (~30-40 bp) (9).
Bacteriophage integrases mediate recombination between phage DNA at the phage attachment
site, a sequence of bases known as attP, and bacteria DNA, the bacterial attachment site, a
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sequence of bases known as attB (figure 2) (9). After the bacteriophage’s genome is integrated
within the bacterial host chromosome it is flanked by the sites attL and attR (9). The attL and
attR sites are considered hybrid because they contain both the partial attP sequence and attB
sequence (figure 2) (9).

Figure 2. Diagram of Integration/Excision Event.
A schematic of bacteriophage genome integration and excision events into and out of host bacterial genome
mediated by integrase and excise proteins (10).

The integrated phage DNA is termed a prophage and its lytic genes are not expressed to drive
production of new phage particles; however, prophages are still copied with the host
chromosome DNA allowing the phage genome to still be reproduced. Some phages can switch
from the lysogenic cycle to the lytic cycle under stressful environmental conditions or
stochastically; in both cases the prophage is excised from the host chromosome (9). The attL and
attR sequences are recognizable by excise, a Recombinational Directionality Factor (RDF)
(Figure 4) (10,11). The RDF promotes prophage excision by redirecting the integrase to the attL
and attR sequences (11). After excision from the host chromosome, the phage DNA triggers the
remaining steps in the lytic cycle (figure 2).

4

1.2.

Antibiotic Resistance

Since the early 1900s, antibiotics have been widely used to treat bacterial infections.
Antibiotics are defined as molecules that inhibit the growth of or kill microorganisms (11).
Penicillin, which is produced from a fungus, was first discovered by Alexander Fleming in 1928.
Since the discovery of antibiotics, there has been the anticipation of antibiotic resistance. During
Fleming’s Nobel Peace Prize lecture in 1945 (awarded for the discovery of penicillin), he warned
of the possibility of antibiotic resistance, “Then there is the danger that the ignorant man may
easily under-dose himself by exposing his microbes to non-lethal quantities of the drug make
them resistant (12).” The Centers for Disease Control and Prevention (CDC) states that
penicillin-R Staphylococcus was identified as antibiotic resistant in 1940, three years prior to
penicillin’s introduction to hospitals in 1943 (13). Antibiotic resistance is a consequence of
natural selection following random mutation and/or horizontal gene transfer. Bacteria that are
resistant to an antibiotic due to mutations(s) in a gene survive and pass on the resistant gene to
other bacteria by horizontal gene transfer or to daughter cells by reproduction. A bacterium is
classified as a multi-drug resistant bacterium, or a “superbug” if the bacterium carries several
resistance genes. The overuse of antibiotics as well as lengthy administration periods contribute
to the increase in antibiotic resistance (14). According to the CDC, each year in the United
States, at least 2 million people are infected with antibiotic resistant bacteria, and for more than
23,000 people, the infection is lethal (13).

1.3.

Bacteriophage Therapy

Shortly after phages were discovered, d’Herelle explored the possibility of treating bacterial
infections with phages. d’Herelle used phages to treat avian typhosis in chickens, Shigellaassociated dysentery (shigellosis) in rabbits, and bacillary dysentery in humans (shigellosis) (3).
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Shortly after those experiments, British medical officer Colonel Morison used phage to treat
cholera outbreaks in India from 1930 to 1935 (15). While phages were commonly used as
antibacterial agents in the early 1900’s, the discovery of penicillin in 1928 led to widespread
abandonment of phages as therapeutic agents in Western medicine. The recent development of
many drug-resistant pathogens has increased the interest to revive and develop phages to treat
bacterial infections again. Strictly lytic phages are preferable to temperate phages as therapeutic
agents because of their ability to effectively lyse the bacterial host compared to their temperate
phage counterparts that allow their bacterial host to persist after the temperate phage DNA is
integrated into the host genome (16).
Phages have advantages over traditional antibiotics for bacterial infections because they
are ubiquitous and host specific. In order to use phages as therapeutic agents, well-characterized
large phage collections and/or automated pipelines that quickly isolate and identify phages are
necessary. Phage therapy represents a potential alternative to antibiotics; however, there is a lack
of clinical studies that were established with quality study design, meaning that the results of
most studies cannot be assessed as statistically significant. Prior to establishment of
bacteriophage therapy in clinical settings, research must be conducted to determine their
effectiveness and ensure that the phage therapy will not negatively affect the patient or elicit
harmful immune responses. Phage therapy case studies have been performed in recent years
under extreme circumstances as final attempts to save patients with severe bacterial infections
when all other treatment options have failed. Other phage therapy studies have been termed
phase I trials, to ensure the safety of administering phages without serious side effects. Phase II
trials are needed to determine the effectiveness of phage therapy to garner FDA approval (16).

6
Conventional phage therapy is the topical, oral, or systemic administration of many
copies of one type of bacteriophage that specifically infects the bacterial infection of the patient.
However, to reduce the emergence of phage resistant mutants, it is ideal for a bacteriophage
cocktail (two or more types of phages) to be used at once or to administer the bacteriophage
along with an antibiotic. Phage cocktails can be specifically tailored to infect more than one
bacterial species. Phage cocktails can also be used to prevent the development of phage resistant
mutants during treatment of bacterial infections. The co-administration of a phage and an
antibiotic requires the host bacterial cell population to perform evolutionary trade-offs that likely
result in reduction of infection (16).
A recent phage therapy study published by Strathdee and colleagues (2017) was
conducted on a 68-year-old diabetic male who exhibited necrotizing pancreatitis complicated by
a multi-drug resistant Acinetobacter baumannii infection. After a chosen bacteriophage cocktail
was tested and shown to infect the patient’s specific bacterial strain, the phage cocktail was
administered intravenously and percutaneously. Results of the phage therapy study were
promising, showing complete clearance of the bacterial infection (17).
Another recent bacteriophage therapy study by Hatfull and colleagues (2019) was
conducted on a 15-year-old female with cystic fibrosis with a disseminated multi-drug resistant
Mycobacterium abscessus infection. Three phages, Muddy, ZoeJ, and BPs, originally isolated on
Mycobacterium smegmatis were determined to also infect the patient’s specific bacterial strain.
After six-months of intravenous administration, twice daily (109 phage particles per dose) of the
cocktail of wild-type Muddy and engineered lytic derivates of ZoeJ and BPs, the patient showed
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clinical improvement including sternal wound closure, improved liver function, and substantial
improvement of infected skin nodules (18).

1.4.

Methicillin- Resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) infections are a global health concern
(19). S. aureus can cause complicated infections and are associated with high rates of morbidity
and mortality. In industrialized nations, S. aureus is the leading cause of bacteremia, which often
causes metastatic infections such as infective endocarditis, arthritis, and osteomyelitis (20). S.
aureus bacteremia can progress to complications such as sepsis and/or septic shock.
Annually in the United States, about 90,000 individuals suffer from MRSA infections and
about 20,000 of those infections are lethal (20). The CDC states that approximately 5% of
patients in hospitals in the U.S. carry MRSA in their nose or on their skin (22). A review of 15
studies established that between 13 and 74 % of worldwide S. aureus infections are resistant to
methicillin. The prevalence of MRSA isolates in Europe exhibits a north-south variation, and 7
of the 29 European countries still report at least 25 % of invasive S. aureus isolates are
methicillin-resistant. In the US, it was estimated in 2005 that 31.8 per 100,000 people were
infected by MRSA and 75% of those infections resulted in S. aureus bacteremia (20).
The incidence of MRSA infections is greatest from healthcare-associated onset acquired
infections. Patients with MRSA infections obtained from healthcare-associated onset often
exhibit comorbidities such as diabetes, decubitus, ulcers, chronic renal disease, prior stroke, and
dementia. The healthcare-associated MRSA strains are commonly associated with pulsed-field
gel electrophoresis (PFGE) USA100 or USA 200 strains and the community-associated MRSA
strains are commonly associated with the USA300 or USA400 strains (20).
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The community-associated strains have a higher expression of toxin producing genes when
compared to the healthcare acquired strains, suggesting that the community-associated strains are
more virulent. Colonization of non-invasive MRSA occurs in 1.3 % of the general population,
the most common site of colonization is the anterior nares, MRSA may also colonize the throat,
axilla, rectum, groin, or perineum (20).

1.5.

JB Bacteriophage

Bacteriophage JB, isolated from dairy cow hair samples by Dr. Nygaard at Montana
State University in the Voyich lab, has the ability to infect methicillin-resistant S.
aureus USA300 strain LAC. JB’s siphoviridae morphology was observed with a transmission
electron microscope (figure 3). The icosahedral capsid was measured at a width of 75 nm, and
the non-contractile tail length as 160 nm (figure 3) (21).

Figure 3. Transmission Electron Micrograph of JB.
JB’s siphoviridae morphology captured by Transmission Electron Microscopy (21).

DNA sequencing and genome annotation characterized JB’s genome as a circularly
permuted 42,683 bp genome with 68 putative protein coding genes, and a G/C content of 35.2%
(figure 4) (21).
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Figure 4. Genome Map.
JB bacteriophage’s annotated genome map cropped into four tiers. Bioinformatically called genes are depicted by
the green and red boxes spanning the length of the genome (21).

1.6.

CRISPR-Cas9

Genetic modification and editing are important biotechnological research tools used to
understand gene functions and biological mechanisms. In the past, gene editing used tools such
as restriction enzymes, recombinases, programmable nucleases, and zinc finger nucleases;
however, these gene editing tools were complex and/or limited in their specificity (22). Once the
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas (CRISPR
associated)9 technology that utilized a single programmable guide RNA (sgRNA) (composed of
crRNA and tracrRNA) was developed by Doudna and colleagues, genomic engineering became
simplified and specific, eliminating the complexity that previously hampered genetic editing
(23). In the past eight years since the newly developed CRISPR-Cas systems were first harnessed
as powerful genomic editing tools, the CRISPR systems have allowed researchers to use the
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CRISPR systems in a wide variety of applications from developing novel genome engineering
programs to clinical trials involving their potential therapeutic applications (22).
CRISPR-Cas9 systems are protein-nucleic acid complexes that provide bacteria and
archaea adaptive immunity from invasion by foreign nucleic acids such as phages (24). There are
three known types of CRISPR/Cas systems, Type I, II, and III (24). In nature, CRISPR systems
are a type of adaptive immune system that use small CRISPR RNAs (crRNAs) and Cas
nucleases to cleave foreign nucleic acids (24). The system is adaptive because it captures and
integrates foreign nucleic acid sequences (30-40 nucleotides) called “spacers” into its CRISPR
loci, between the partially palindromic DNA repeats of crRNA (24). When the foreign nucleic
acid sequence invades the cell, the host cell liberates the crRNAs and combines with a Cas
protein to form an effector complex that recognizes the nucleic acid sequence (protospacer) that
is complimentary to the crRNA (24).
The type II Cas9 system is the most used CRISPR-Cas system for genome editing. The crRNA
of this system relies on tracrRNA (trans-activating RNA), which has complimentary sequence to
the repeat-derived sequences in crRNA (24). The tracrRNA and the precursor crRNA base pair
to form a mature crRNA and associate with the Cas9 enzyme to form a complex (24). The
mature crRNA recognizes a short motif known as a protospacer adjacent motif (PAM) in the
target DNA sequence and guides the Cas9 enzyme to the target DNA sequence to create the
dsDNA break (24).
In many of the CRISPR/Cas systems a PAM sequence is absent from the host genome
but preserved in the foreign genome, thereby distinguishing between self and non-self (24). In
the Type II systems, the PAM is a consensus sequence that occurs downstream of the crRNA
binding sequence within the target DNA (24). The PAM sequence is essential for the Cas9
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enzyme to introduce dsDNA breaks, and is required to license duplex unwinding, strand
invasion, and the formation of an R-loop structure (24). The Cas9 protein contains domains that
are homologous to HNH and RuvC-like endonucleases, and each domain cleaves one strand of
DNA. The HNH domain cleaves the DNA strand that is complimentary to the sgRNA and
the RuvC-like domain cleaves the non-complimentary DNA strand (24).
tracrRNA substantially enhances the specificity and binding of the Cas9 protein to target
DNA. Cas9 systems alone or Cas9-cRNA have decreased DNA binding at target sequences,
indicating that tracrRNA enhances target DNA recognition by orienting the crRNA correctly so
interaction with the complementary strand of DNA can occur. In nature, species that
have maintained specificity of dual RNA-guided cleavage of DNA indicate that Cas9, tracrRNA
and crRNA repeat have co-evolved. Additionally, efficient target DNA cleavage occurs
when there is a contiguous stretch of at least 13 base pairs between the crRNA and the target
DNA site proximal to the PAM (24).
Doudna and colleagues (2012), harnessed the CRISPR-Cas9 system to direct the
Cas endonuclease to a target sequence of plasmid DNA that bears a protospacer sequence
complimentary to a mature crRNA and a PAM sequence (23). Genomic editing nucleases, such
as the Cas9 nuclease, take advantage of innate cellular DNA repair systems (23). The nucleases
generate the DNA breaks that induce cellular damage responses such as non-homologous endjoining (NHEJ) or homology-directed repair (HDR) (22). NHEJ response is error-prone and
often leads to insertion or deletion mutations (indels) within the DNA (22). NHEJ is often
induced to create gene knockouts by introducing a Cas9 cleavage to an exon to generate frameshift mutations to prematurely introduce stop codons and disrupt gene expression
(22). Megabase-size deletions can also be created by two targeted, double-stranded breaks and
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relying on NHEJ to introduce a large deletion (22). HDR is less error prone; HDR is induced
after introduction of the Cas9 nuclease and a repair template to the target sequence of DNA. The
homology-directed repair can result in precise genome alterations such as the deletion of large
sequences (figure 5) (22).

Figure 5. Schematic of CRISPR/Cas9 Deletion, Insertion, or Modification Event.
CRISPR/Cas9 creates a double stranded break upstream of the PAM sequence within the target DNA sequence.
Homologous recombination of the genomic DNA with the provided donor template results in a precise deletion,
insertion, or modification (22).

Doudna and colleagues devised an effective and simple method to program the Cas9
endonuclease family with a single guide RNA molecule that directs the Cas enzyme cleavage of
specific sequences of DNA to generate dsDNA breaks for genome targeting and editing (23).

1.7.

Genomic Editing of Bacteriophages with CRISPR/Cas9

The recent ability to harness CRISPR-Cas9 as a tool for genomic engineering, allows
researchers to efficiently edit bacteriophage genomes to characterize and understand gene
functions. In nature, CRISPR systems are abundant in a broad range of species (23). The
CRISPR system is adaptive because it captures and integrates foreign nucleic acid sequences
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(30-40 nucleotides) called “spacers” into its CRISPR loci, between the partially palindromic
DNA repeats of crRNA (23). When foreign nucleic acid sequence invades the cell, the host
cell generates crRNAs that combine with a Cas protein to form an effector complex
which recognizes the nucleic acid sequence (protospacer) complimentary to the crRNA
(23). Bacteriophage genomes can be modified to a desired construct by providing a donor DNA
segment that bears the desired mutations within the protospacer region flanked by sequences that
are homologous to the phage genome on both sides (22). To construct the desired mutant, the
host cell uses the donor DNA segment after the Cas9 cleavage as a template for homologous
recombination (22).
Chen and colleagues designed and constructed a CRISPR/Cas9 expression plasmid,
pCasSA, to harness the CRISPR/Cas9 system for genomic editing in S. aureus (28). The pCasSA
plasmid contains a strong S. aureus rpsL promoter to drive the expression of the Cas9 protein, a
strong cap/1A promoter to drive the expression of the gRNA, a BsaI cloning site for the
assembly of spacers, a XbaI/Xhol cloning site for repair arms, a chloramphenicol (Cm) resistance
marker for screening in S. aureus, a kanamycin (KanR) resistance marker for screening in
E.coli, repF, a temperature sensitive origin of replication for S. aureus, and ColE1, a replication
origin for E. coli (figure 6) (28).
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Figure 6. pCasSA plasmid.
pCasSA vector map of the cloning sites and antibiotics resistance markers. The XbaI and XhoI sites are available for
the insertion of repair arms DNA sequence and the BsaI sites are available for the insertion of gRNA sequence (28).

JB phage contains a putative gene encoding for an integrase protein; the presence of this
gene indicates that JB is likely a temperate bacteriophage. In order for JB to be used for
therapeutic purposes, it is critical that a high proportion of phage infections results in bacterial
cell lysis is critical for eradication of MRSA bacterial infections. It is therefore essential to delete
the integrase gene in JB phage in order to create a strictly lytic JB phage derivative.
Within phage genomes it is not uncommon to find genes that encode putative toxin proteins.
Abedone and LeJeune (2005) suggest that through genetic symbiosis between phage and bacteria
after genome integration, toxin genes have remained prevalent in phages. These virulence factors
contribute to the development of infectious diseases in eukaryotes (24). JB phage encodes a
putative toxin protein; through CRISPR-Cas9 gene editing technology it is possible to remove
the toxin gene, which is a necessary step before the JB phage could be used therapeutically in
humans to treat MRSA bacterial infections.
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1.8.

Project Aims

Experiments were designed using repair arms to delete the cluster of four reverse genes
(genes 30-33) within the JB genome after CRISPR-Cas9 mediated breaks (figure 7).

Figure 7. Schematic of the four genes to be deleted from the JB genome.
Gene number 30- putative integrase, Gene number 31- hypothetical protein with no known function, Gene
number 32- putative toxin, Gene number 30- putative transcriptional regulator.

1.9.

Experimental Design

A series of steps were planned to (1) construct a plasmid with gRNA and repair arms
(figure 8); (2) introduce the plasmid into S. aureus RN4220; (3) infect the strain harboring the
plasmid with the JB bacteriophage (figure 9); (4) isolate released phages by plaque assay on S.
aureus PS88; and (5) screen resultant plaques for JB bacteriophage deletion mutant with PCR
and DNA sequencing.

Figure 8. pCasSA-mediated genome editing.
Schematic of target DNA genomic editing after the introduction of the repair arms and sgRNA into the pCasSA
plasmid (25).
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Figure 9. Phage Engineering.
Schematic of phage engineering after incorporation of the CRISPR/Cas9 expression vector into S. aureus RN4220.
Expression of the Cas9 complex within S. aureus RN4220 after infection with the JB phage results in a doublestranded break within the JB DNA sequence that is homologous to the gRNA. Homologous recombination with the
provided repair arms results in a deletion mutant JB phage (24).
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2. Methods
2.1. Preliminary bioinformatic analysis of genes 30-33 within the JB
bacteriophage genome
Initial JB phage genome annotation by Dr. Gregory determined the location and starts of
genes 30-33 and their protein coding potential (21).
Additional bioinformatic analysis of genes 30-33 was done with the NCBI database,
Basic Local Alignment Sequence Tool (BLAST) (25). Protein BLAST (BlastP) was performed
by inputting genes 30-33’s amino acid sequences into the BlastP tool (25). The BlastP compared
the protein sequences of genes 30-33 to sequence databases and calculated the statistical
significance of sequence alignment (25).

2.2.

Construction of the pHS1 plasmid
Purification of the pCasSA plasmid

pCasSA, CRISPR-based E. coli/S. aureus temperature-sensitive plasmid for genome
editing in S. aureus was purchased from Addgene (Addgene plasmid #982111;
http://n2t.net/addgene:98211; RRID: Addgene_98211) (26) (figure 10).
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Figure 10. pCasSA (28).
A vector map of the pCasSA plasmid from Addgene.

The pCasSA plasmid was received within Escherichia coli in a bacterial agar stab. A
sterile pipette tip was inserted into the bacterial agar stab, and the E. coli containing the plasmid
were streaked using sterile technique onto a Luria Broth (LB) plate containing 50 µg/mL
kanamycin. The plate was incubated at 37oC overnight. Isolated colonies were observed and
picked into 4 mL of LB broth containing 50 µg/mL kanamycin and incubated overnight at 37oC
with shaking at 250 rpm. The bacterial cultures were pelleted by centrifugation at 12,000 rpm for
5 minutes. The supernatant was decanted, and the plasmid was purified from the pelleted cells
using a Thermo Scientific GeneJET Plasmid Miniprep Kit (K0503).
DNA Sequencing of pCasSA as a negative control for repair arms
and gRNA
Purified pCasSA plasmid (100 ng/µL in a total volume of 10 µL) and aliquots of primers
A, D, and F (50 ng/µL in a total volume of 10 µL) were sent to Functional Biosciences for
DNA sequencing.
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Amplification and Purification of the Left and Right Repair Arms
The JB bacteriophage genome six-frame translation and the genome annotation were
used to determine the location of the four genes to be knocked out (19). Flanking left and right
repair arm sequences were chosen (~1 kb each) (Appendix A). Primers to isolate the repair arms
from the JB genome using polymerase chain reaction (PCR) were designed with flanking
sequences for seamless cloning into the pCasSA plasmid’s XbaI and XhoI cloning sites using
NEBuilder Hifi DNA Assembly (Appendix B).
JB bacteriophage was amplified on S. aureus PS88 Rosenbach (ATCC 33742). The lysate
was diluted 1:1000 in sterile nuclease-free water for use as a DNA template in the PCR reaction.
PCR amplification of the left arm was performed by adding 1 µL JB lysate (5.0 x 105 pfu/mL)
diluted in sterile nuclease-free water (1:1000), 12.5 pmol of primer A (Appendix B), 12.5 pmol
of primer B (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix and the final
volume was brought to 25 µL. PCR amplification of the right arm was performed by the addition
of 1 µL JB lysate (1:1000) diluted in sterile nuclease-free water, 12.5 pmol of primer C, 12.5
pmol of primer D, and Promega 2X GoTaq Green Mastermix for a final volume of 25 µL. The
reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle (96oC -2 min.); 30
cycles (96oC- 15 sec., 60oC- 45 sec, 72o- 1 min 30 sec); 1 cycle (72oC- 5 minutes); indefinite
hold at 4oC].
The reaction products were analyzed by agarose gel electrophoresis on a 0.8% agarose
gel stained with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. Ten microliters of the PCR
products were flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder. DNA bands were visualized
on a Bio-Rad Gel Doc XR.
To purify the left and right repair arm PCR products, the bands were excised from the gel
with sterile scalpels. The bands were purified using the ThermoFisher GeneJET Gel Extraction
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Kit (K0692). To verify efficient recovery of the left and right repair arm DNA fragments, 5 uL
the purified products plus 1 µL of 6X loading dye were analyzed by agarose gel electrophoresis
flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder on a 0.8% agarose gel stained with 4x10-4
mg/mL EtBr at 130 V in 1X TBE Buffer. DNA bands were visualized on a Bio-Rad Gel D XR.
Annealing of the Left and Right Repair Arms
For efficient cloning of the repair arms into the pCasSA plasmid, the purified
PCR products of the left and right repair arms were annealed using the NEBuilder Hifi DNA
Assembly Cloning Kit (NEB #E5520). The annealed product was diluted (1:10) in sterile
nuclease-free water and used as a DNA template for PCR. PCR amplification of the annealed
arms was performed by adding 1 µL annealed product (1:10), 12.5 pmol of primer A (Appendix
B), 12.5 pmol of primer D (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix
in a final volume of 25 µL. The reactions were placed in a Bulldog Bio LifeECO Thermal
Cycler [1 cycle (96oC -2 min.); 30 cycles (96oC- 15 sec., 60- 45 sec, 720- 1 min 30 sec); 1 cycle
(72oC- 5 minutes); indefinite hold at 4oC]. To verify successful annealing of the left and right
repair arms, 5 µL the annealed product, plus 1 µL of 6X loading dye were analyzed by agarose
gel electrophoresis flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder on a 0.8% agarose gel
stained with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. DNA bands were visualized on a
Bio-Rad Gel Doc XR.
Insertion of the Repair Arms into the pCasSA plasmid
Two micrograms of the pCasSA plasmid were digested with 1 unit of XbaI (New England
BioLabs) and 5 µL of 10X Cutsmart Buffer (New England BioLabs) in a 50 µL reaction. The
reaction was incubated at 37oC for one hour, and 1 unit of XhoI (New England BioLabs) was
added for a sequential digest. The reaction was incubated at 37oC overnight. The digestion
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reaction was purified using the QIAquick PCR Purification kit. To maintain the correct pH of the
purification product, 10 µL of 3M NaOAc was added to the sample to ensure binding of the
plasmid to the column. To confirm efficient digested plasmid recovery, 5 µL of the purified
product was analyzed by agarose gel electrophoresis, next to one lane (0.5 µg/lane) of 1 KB
NEB ladder and electrophoresed on a 0.8% agarose gel stained with 4x10-4 mg/mL EtBr in 1X
TBE Buffer. DNA bands were visualized on a Bio-Rad Gel Doc XR.
The annealed repair arms were inserted into the vector at a 1:2 ratio using the NEB Hifi
DNA Assembly Kit (NEB #E5520). The assembly reaction (2 uL) was subsequently transformed
into NEB 10-beta Competent E. coli (High Efficiency, NEB #C3019). The transformed cells
were plated with sterile glass beads on LB plates with 50 µg/mL kanamycin and incubated at
37oC overnight. To isolate the pHS1 plasmid, half of each isolated colony was picked with a
sterile pipette into 4 mL LB broth with 50 µg/mL kanamycin and incubated at 37oC with shaking
at 250 rpm overnight. Bacterial cultures were pelleted by centrifugation at 12,000 rpm for five
minutes. The supernatant was decanted and the plasmid was purified from the pelleted cells
using a Thermo Scientific GeneJET Plasmid Miniprep Kit (K0503). The miniprep samples of
pHS1 were stored at -20oC.
To screen the bacterial colonies for the pHS1 plasmid, the other half of each isolated
colony was picked with a sterile pipette into 999 µL of sterile nuclease-free water. PCR
amplification of the annealed arms was performed to screen the colonies for the pHS1 plasmid
by adding 1 µL of the suspended colonies, 12.5 pmol of primer A (Appendix B), 0.5 uL of 25
µM of primer D (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix in a final
volume of 25 µL. The reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle
(96oC -2 min.); 30 cycles (96oC- 15 sec., 60oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5

22
minutes); indefinite hold at 4oC]. The reactions were analyzed by agarose gel electrophoresis on
a 0.8% agarose gel stained with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. Ten microliters
of the PCR reactions were flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder. DNA bands were
visualized on a Bio-Rad Gel Doc XR.
Cultures from colonies that were confirmed to contain the pHS1 plasmid were made into
glycerol stocks; 500 µL of the bacterial culture was mixed with 500 µL of sterile 40% glycerol in
a 2 mL cryovial. The glycerol stocks of E. coli containing pHS1 were stored at -80oC.

2.3.

Construction of the pHS3 plasmid
Creation of the gRNA

To generate the pHS3 plasmid, a gRNA (Appendix A) was designed from the JB phage
genome and ligated into the pHS1 plasmid. The gRNA was designed by identifying a sequence
within the cluster of four genes to be knocked-out that was upstream of a PAM sequence 5’ to 3
(located within gene 32 at 29,030-29,050). The oligonucleotides were designed and ordered from
Integrated DNA Technologies (IDT) (Appendix A). The oligos were resuspended in sterilenuclease free water to a concentration of 50 µM. The oligonucleotides were phosphorylated by
adding 50 µM of primer F (Appendix B) and 50 µM of primer G (Appendix B) 1 µL of 10X T4
DNA ligase buffer, and 1 µL of 10 U/µL T4 polynucleotide kinase. The phosphorylation reaction
was incubated at 37oC for one hour. After phosphorylation, the oligonucleotides were annealed
by adding 2.5 µL of 1M NaCl to the phosphorylation reaction. The sample was transferred to a
sterile PCR tube and the reaction was placed in a Bulldog Bio LifeECO Thermal Cycler at 95oC
for 3 minutes and slowly cooled to room temperature. The annealed oligos were diluted 1:20
with sterile nuclease-free water.
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Golden Gate Assembly
To introduce the gRNA into the pHS1 plasmid, Golden Gate Assembly was used. To a
sterile PCR tube, 2 µL of 20 fmol pHS1 plasmid, 1 µL of 100 fmol annealed oligos, 1 µL of 10X
T4 DNA ligase buffer, 0.5 uL of 1 U/uL T4 DNA ligase, and 0.5 µL of BsaI-HFv2 were added.
The Golden Gate assembly reaction was placed in a Bulldog Bio LifeECO Thermal Cycler at
(37oC for 2 min, 16oC for 5 min) for 25 cycles, followed by 50oC for 5 min, 80oC for 15 min, and
held at 10oC.
Transforming E. coli with the pHS3 plasmid and screening
The pHS1/gRNA (pHS3) Golden Gate assembly reaction was subsequently transformed
into NEB 10-beta Competent E. coli (High Efficiency, NEB #C3019) using the NEBuilder Hifi
DNA Assembly Kit. The transformed cells were plated with sterile glass beads on LB plates with
50 µg/mL Kanamycin at 37oC overnight. To purify the pHS3 plasmid, half of each isolated
colony was picked with a sterile pipette into 4 mL LB broth with 50 µg/mL kanamycin and
incubated with shaking at 37oC at 250 rpm overnight. Bacterial cultures were pelleted by
centrifugation at 12,000 rpm for five minutes. The supernatant was decanted, and the plasmid
was purified from the pelleted cells using a Thermo Scientific GeneJET Plasmid Miniprep Kit
(K0503). The purified pHS3 plasmid was stored at -20oC.
To screen the bacterial colonies for the pHS3 plasmid, the other half of each isolated
colony was picked with a sterile pipette into 999 µL of sterile nuclease-free water. PCR
amplification of a region in the plasmid between the left repair arm and gRNA was performed to
screen for the insertion of the gRNA and to confirm the creation of the pHS3 plasmid by adding
1 µL diluted colony (1:1000), 12.5 pmol of primer E (Appendix B), 12.5 pmol primer F
(Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix for a final volume of 25
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µL. The reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle (96oC -2
min.); 30 cycles (96oC- 15 sec., 52oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5 minutes);
indefinite hold at 4oC].
The reactions were analyzed by agarose gel electrophoresis on a 0.8% agarose gel stained
with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. Ten microliters of the PCR reactions were
flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder. DNA bands were visualized on a Bio-Rad
Gel Doc XR.
Cultures from colonies that were confirmed to contain the pHS3 plasmid were made into
glycerol stocks, 500 µL of the bacterial culture were mixed with 500 µL of sterile 40% glycerol
in a 2 mL cryovial. The glycerol stocks of pHS3 were stored at -80oC.

2.4.

Transformation of the pHS3 plasmid into S. aureus
Generating High Concentrations of Plasmids for electroporation into
S. aureus RN4220

From the E. coli glycerol stock of the pCasSA plasmid, a small scraping was streaked
onto an LBA plate containing 50 µg/mL kanamycin for isolated colonies and incubated
overnight at 37oC. Five isolated colonies were picked with a sterile pipette tip into 5 mL of LB
containing 50 µg/mL kanamycin and incubated at 250 rpm at 37oC overnight. The bacteria were
pelleted by centrifugation for 5 minutes at 12,000 rpm. The supernatant was discarded and the
pCasSA plasmid from the first culture was purified using the Thermo Scientific GeneJET
Plasmid Miniprep Kit (K0503). The purified pCasSA sample from the first culture was used to
elute the purified plasmid from the second culture of pCasSA. The pCasSA plasmid eluate was
used to sequentially to elute the purified plasmid from the remaining columns to generate a high
concentration (~500-1,000 ng/µL) of pCasSA plasmid for electroporation. The steps were
repeated for the pHS1 and pHS3 plasmids.
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Culturing S. aureus RN4220
The S. aureus RN4220 glycerol stock was stored at -80oC. From the freezer stock of S.
aureus RN4220, a sterile pipette was used to add a small scraping of the S. aureus RN4220
glycerol stock to 20 mL of TSB. The culture flask was incubated at 37oC with shaking at 250
rpm overnight for 12 hours.
Generation of Electrocompetent S. aureus RN4220
Two sterile culture flasks containing 100 mL TSB were inoculated with 1 mL of
overnight culture of S. aureus RN4220 and incubated at 37oC at 250 rpm until the OD600 reached
0.5 (~3 hours). The cells were transferred to four sterile 50 mL conical tubes and placed on ice
for 15 minutes. The cells were pelleted by centrifugation at 12,000 rpm, 10 min, 4oC. The
supernatant was removed and discarded without disturbing the pellet. Each aliquot was washed
with 50 mL of ice-cold sterile deionized water. The cells were centrifuged for 10 minutes at
4,000xg at 4oC. The supernatant was removed and discarded without disturbing the pellet. The
pellet was resuspended in 25 mL ice-cold sterile deionized water. Two resuspended bacterial
pellets were combined into one 50 mL conical tube and centrifuged for 10 minutes at 4,000xg at
4oC. The supernatant was removed and discarded without disturbing the bacterial pellet. The two
remaining pellets were resuspended in 16 mL ice-cold sterile 10% glycerol, and centrifuged for
10 minutes at 4,000xg at 4oC. The supernatant was removed and discarded without disturbing the
bacterial pellet. The pellet was thoroughly resuspended with 1 mL ice-cold sterile 10% glycerol,
and transferred to a sterile 1.5 mL microcentrifuge tube, and centrifuged for 5 minutes at 5,000xg
at 4oC. The supernatant was removed without disturbing the bacterial pellet. The pellet was
resuspended in 700 µL ice-cold sterile 10% glycerol. The bacteria were divided into pre-chilled
70 µL aliquots in 0.5 mL microcentrifuge tubes and frozen immediately at -80oC.
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Transforming pHS3 into S. aureus RN4220 and screening
The electrocompetent cells were retrieved from the -80oC and thawed on ice for 10
minutes. TSA was aliquoted in 250 µL increments into 1.5 mL microcentrifuge tubes and prewarmed at 37oC. To the thawed electrocompetent S. aureus, 1.2 ug of plasmid was added and
gently mixed by pipetting. The transformation mixture was transferred to a pre-chilled
ThermoFischer Scientific cuvette with a 0.2 cm electrode gap. The cuvette was placed in the
sample chamber of a Bio-Rad Gene Pulser II/ Pulse Controller Plus/ Capacitance Extender Plus
and pulsed once at 2.5 kV, capacitor at 25 µF, and parallel resistor at 200 Ohms, yielding a field
strength of 12.5 kV and a time constant of -2.5 ms. The cells were immediately mixed into the
250 µL of pre-warmed TSB. The mixture was transferred to a sterile culture tube and incubated
at 30oC at 500 rpm for 5 minutes and 250 rpm for 55 minutes. The aliquots were plated in 20 µL
and 200 uL aliquots on TSA containing 10 µg/mL chloramphenicol for 36 hours at 30oC.
To screen the bacterial colonies for the pHS3 plasmid, 20 colonies were picked with a
sterile pipette into 999 µL of sterile nuclease free water. PCR amplification of the left and right
repair arms to confirm the structure of the pHS3 plasmid was performed by adding 1 µL
resuspended colony, 12.5 pmol of primer A (Appendix B), 12.5 pmol of primer D (Appendix
B), and 12.5 µL of Promega 2X GoTaq Green Mastermix to a final volume of 25 µL. The
reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle (96oC -2 min.); 30
cycles (96oC- 15 sec., 60oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5 minutes); indefinite
hold at 4oC]. The reaction products were analyzed by agarose gel electrophoresis on a 0.8%
agarose gel stained with 4x10-4 mg/mL EtBr at 130 kV in 1X TBE Buffer; 10 µL of the PCR
reactions, were flanked by 0.5 µg/lane of 1 KB GeneRuler Plus Ladder. DNA bands were
visualized on a Bio-Rad Gel Doc XR.
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Transformed colonies that were confirmed to contain the plasmid were picked with a
sterile pipette into 3 mL TSB containing 10 µg/mL of chloramphenicol and incubated overnight
at 250 rpm at 30oC. The bacterial cultures were made into glycerol stocks: 500 µL of the
bacterial culture was combined with 500 µL of sterile 40 % glycerol in a 2 mL cryovial. The
glycerol stocks of plasmids were stored at -80oC.

2.5.

Infection of S. aureus RN4220-pHS3 with bacteriophage JB
Liquid infection of S. aureus RN4220-pHS3 with bacteriophage JB

An isolated colony of S. aureus RN4220-pHS3 was picked into 3 mL of 10 µg/mL
kanamycin, TSB (supplemented with 25% dextrose and 0.1 M CaCl2) and grown overnight at
30oC with shaking at 250 rpm. An isolated colony of S. aureus RN4220 was picked into 3 mL of
TSB++ and grown overnight at 30oC with shaking at 250 rpm. Ten microliters of JB lysate
(concentration of the JB lysate: 5.0 x 105 pfu/mL) and 3 mL of TSB (supplemented with 25%
dextrose and 0.1 M CaCl2) were added to 250 µL of S. aureus RN4220-pHS3 and incubated for
36 hours at 37oC with shaking at 250 rpm. Ten microliters of JB lysate (5.0 x 105 pfu/mL) and 3
mL of TSB (supplemented with 25% dextrose and 0.1 M CaCl2) were added to 250 µL of S.
aureus RN4220 and incubated for two nights at 30oC with shaking at 250 rpm.
Lysate creation of putative JB deletion mutant (JB30-33)
After a 36-hour incubation, the liquid JB infection culture of S. aureus RN4220-pHS3
was centrifuged at 2,000 rpm for 5 minutes. Three milliliters of supernatant were filtered through
a 0.22 µm filter into a sterile 15 mL conical tube.
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Plaque Assay of S. aureus ATCC 33742 (PS88) with bacteriophage JB
and putative deletion mutant JB30-33
An isolated colony of S. aureus ATCC 33742 (PS88) was picked into 3 mL of TSB
(supplemented with 25 % dextrose and 0.1 M CaCl2) and grown overnight at 30oC with shaking
at 250 rpm. Ten microliters of JB lysate (5.0 x 105 pfu/mL) and 3 mL of TSB (supplemented
with 25 % dextrose and 0.1 M CaCl2) were added to 250 µL of S. aureus RN4220-pHS3 and
incubated at room temperature for 15 minutes. Five milliliters of molten top agar (65oC) of
TSTA (supplemented with 25 % dextrose and 0.1 M CaCl2) , was added to the culture of S.
aureus RN4220 with JB phage and poured onto a TSA (supplemented with 25 % dextrose and
0.1 M CaCl2) plate, after the top agar solidified, the plate was incubated overnight at 30oC. Ten
microliters of JB lysate (5.0 x 105 pfu/mL) and 3 mL of TSB (supplemented with 25 % dextrose
and 0.1 M CaCl2) were added to 250 uL of S. aureus RN4220 and incubated at room temperature
for 15 minutes. Five milliliters of molten top agar (65oC) of TSTA (supplemented with 25 %
dextrose and 0.1 M CaCl2) , was added to the culture of S. aureus RN4220 with JB phage and
poured onto a TSA (supplemented with 25 % dextrose and 0.1 M CaCl2) plate, after the top agar
solidified, the plate was incubated at 30oC.

2.6.

Confirmation of deletion mutant JB30-33.
Screening plaques for deletion mutant JB30-33 by PCR.

Plaques from JB30-33 infection on S. aureus ATCC 33742 (PS88) were picked into 50
µL of sterile nuclease-free water. Plaques from wild-type JB infection of S. aureus ATCC 33742
(PS88) were picked into 50 µL of sterile nuclease-free water. An isolated colony of S. aureus
ATCC 33742 (PS88) was picked into 1000 µL of sterile nuclease-free water as a negative
control. Purified pHS3 was picked into 1000 µL of sterile nuclease-free water as a positive
control. PCR amplification of the left and right repair arms was used to confirm the presence or
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absence of genes 30-33 within the JB phage genome. One microliter of template DNA
(resuspended plaque or plasmid control), 12.5 pmol of primer A (Appendix B), 12.5 pmol of
primer D (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix and brought to a
final volume of 25 µL. The reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1
cycle (96oC -2 min.); 30 cycles (96oC- 15 sec., 60oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5
minutes); indefinite hold at 4oC]. The reactions were analyzed by agarose gel electrophoresis on
a 0.8 % agarose gel stained with 4x10-4 mg/mL EtBr at 130 kV in 1X TBE Buffer, 10 µL of the
PCR reactions, were flanked by 0.5 µg/lane of 1 KB GeneRuler Plus Ladder. DNA bands were
visualized on a Bio-Rad Gel Doc XR.
DNA sequencing of PCR amplicons from wild-type JB and JB30-33.
PCR products of amplified sequence from putative deletion mutant JB30-33, wild-type
JB, S. aureus ATCC 33742 (PS88), and sterile-nuclease free water (figure 28) were purified with
a QIAquick PCR purification kit. Purified PCR products and 10 µM aliquots of primers A, D,
and F were sent to Functional Biosciences for DNA sequencing.
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3. Results and Discussion
3.1. Preliminary bioinformatic analysis of genes 30-33 within the JB
bacteriophage genome
Annotated gene #30 is 1047 bp in length, 5’ (26,799-27,845) 3’ within the JB genome.
Bioinformatic analysis of gene #30 revealed that it putatively encodes for a site-specific
integrase. BlastP analysis of gene 30 confirmed significant alignment (>99 %) for several S.
aureus-encoded site-specific integrases (figure 11).

Figure 11. BlastP analysis of Gene 30.
Figure showing significant similarity of JB gene 30 protein sequence to site-specific integrases within the
GenBank database.

Gene #31 is 930 bp in length, 5’ (27,907-28,836) 3’ within the JB genome. Bioinformatic
analysis of gene #31’s gene product revealed that it putatively encodes domain-containing
protein without a known function. BlastP analysis of gene #31 protein sequence confirmed
significant alignment (>98 %) for several S. aureus domain-containing proteins (figure 12).
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Figure 12. BlastP analysis of Gene 31.
Figure showing significant similarity of JB gene 31 product’s amino acid sequence to domain-containing
proteins within the GenBank database.

Gene #32 is 459 bp in length, 5’ (28,855-29,313) 3’ within the JB genome. Bioinformatic
analysis of gene #32’s product revealed that it putatively encodes a toxin protein. BlastP analysis
of gene #32 protein sequence confirmed significant alignment (>98 %) for several S. aureusencoded toxin proteins (figure 13).

Figure 13. BlastP analysis of Gene 32.
Figure showing significant similarity of JB gene 32 product’s amino acid sequence to toxins within the GenBank
database.

32
Gene #33 is 315 bp in length, 5’ (29,335-29,649) 3’ within the JB genome. Bioinformatic
analysis of gene #33’s product revealed that it putatively encodes a helix-turn-helix
transcriptional regulator protein. BlastP analysis of gene #33’s protein sequence significant
alignment (>98 %) for several S. aureus encoded helix-turn-helix transcriptional regulator
proteins (figure 14).

Figure 14. BlastP analysis of Gene 33.
Figure showing significant similarity of JB gene 32’s amino acid sequence to helix-turn-helix transcriptional
regulator proteins within the GenBank database.

3.2.

Construction of the pHS1 plasmid
Purification of the pCasSA plasmid

Isolated colonies were grown from the E. coli bacterial stab on an LBA plate containing
50 µg/mL kanamycin suggesting the presence of the pCasSA plasmid (figure 15).

Figure 15. E. coli containing the pCasSA plasmid.
A streak plate showing isolated colonies of E. coli containing the pCasSA plasmid.
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Following purification of the pCasSA plasmid from liquid cultures of the isolated
colonies of E. coli, Nanodrop analysis determined the concentration of the purified plasmid to
be 160.8 ng/µL with a 260/280 ratio of 1.95 (figure 16).

Figure 16. Purified pCasSA plasmid.
Graph and DNA concentrations of the pCasSA plasmid following Nanodrop analysis.

DNA sequencing of pCasSA as a negative control for repair arms and
gRNA
To establish the purified plasmid lacked DNA sequences similar to JB Bacteriophage,
DNA Sequencing reactions were run. As expected, DNA sequencing of the purified pCasSA
plasmid did not produce a DNA sequence from primers A (figure 17). The sequencing results
show that the repair arms are not within the template pCasSA plasmid.

Figure 17. DNA Sequencing of pCasSA.
The figure shows sequencing results from pCasSA with primer A.
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DNA sequencing of the purified pCasSA plasmid also did not produce a DNA sequence
from primer F (figure 18). The sequencing results show that the gRNA is not within the template
pCasSA plasmid.

Figure 18. DNA Sequencing of pCasSA.
The figure shows sequencing results from pCasSA with primer F.

Amplification and Purification of the Left and Right Repair Arms
Polymerase chain reaction amplification of the left and right repair arms yielded DNA
bands at the expected sizes of 906 bp and 971 bp, respectively (figure 19). The gel
electrophoresis image demonstrates the successful amplification of the left and right flanking
sequences of the genes of interest (30-33).
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Figure 19. Gel Electrophoresis Images of Left and Right Repair Arms.
Gel a.) Gel electrophoresis of left and right repair arms amplified from JB lysate with Polymerase Chain
Reaction; L- GeneRuler 1 kb DNA ladder, 1- Left repair arm (expected size = 906 bp), 2- Right repair arm
(expected size= 971 bp). Gel b.) Gel electrophoresis of left and right repair arms after excision and purification from
gel a; L- GeneRuler 1 kb DNA ladder, 1- Left repair arm (expected size = 906 bp), 2- Right repair arm (expected
size= 971 bp).

Annealing of the Left and Right Repair Arms
DNA assembly of the left and right repair arms yielded a DNA band at the expected size
of 1,877 bp (figure 20). The presence of the band at 1,877 bp indicates that the left and right
repair arms were covalently joined.

Figure 20. Gel Electrophoresis Images of Annealed Left and Right Repair Arms.
Gel electrophoresis of annealed repair arms after DNA assembly; L- GeneRuler 1 kb DNA ladder, 1-annealed left
and right repair arms (expected size = 1,877 bp).
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Insertion of the Repair Arms into the pCasSA plasmid
Supercoiled and circularized plasmids electrophoretic mobility vary from linear; purified
plasmids often show two bands (figure 21, lane 1). Linearization of the pCasSA plasmid
occurred after restriction enzyme digestion with XbaI and XhoI and was visualized with gel
electrophoresis. The linearized band was observed at the expected size of 10,231 bp (figure 21).

Figure 21. Gel Electrophoresis image of linearized pCasSA.
Gel a.) Gel electrophoresis of linearized pCasSA; L- GeneRuler 1 kb DNA ladder, 1- Circularized and supercoiled
pCasSA (expected size= 10,240 bp) 2- linearized pCasSA (expected size= 10,231 bp). Gel b.) Gel electrophoresis of
linearized pCasSA after excision and purification from gel a; L- GeneRuler 1 kb DNA ladder, 1- linearized pCasSA
(expected size = 10,231 bp bp).

To create pHS1, linearized plasmid and repair arms were joined by NEB Hi-Hi DNA
Assemby and transformed into E. coli. The resultant colonies of E. coli that putatively contained
the pHS1 plasmid grew on an LB plate containing 50 µg/mL of kanamycin (figure 22).

Figure 22. Colonies of E. coli putatively containing the pHS1 plasmid.
Left plate- Isolated colony growth of E. coli putatively containing pHS1. Right Plate- Negative control
plate with minimal colony growth.
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Polymerase chain reaction to screen for the repair arms (expected size of 1,877 bp) of the
pHS1 plasmid within isolated E. coli colonies (figure 22) using primers A and D, revealed the
expected product size for the presence of the pHS1 plasmid within 16 of 20 picked colonies after
transformation (refer to figure 23). Colonies picked from the pCasSA (negative control plate)
(figure 22) did not yield bands for the repair arms. The positive controls of the purified
assembled arms yielded bands of the expected size, 1,877 bp (figure 23).
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Figure 23. Gel Electrophoresis of PCR products to screen for the presence of pHS1 within E. coli.
L- GeneRuler 1 kb ladder, 1-20- picked colonies of the putative pHS1 plasmid (figure 22, left plate), 21-22
– picked colonies of negative control, vector only (figure 22, right plate), 23-24- picked colonies of the negative
control, pCasSA plasmid commercially available within E. coli (refer to figure 15), 25-26- positive control, purified
assembled arm products.

Confirmation of the repair arms within the pHS1 plasmid
DNA sequencing results of the pHS1 plasmid with primer A (figure 24) (Appendix B)
aligned with the JB wild-type sequenced genome repair arms using BlastN sequence analysis,
confirming the presence of the repair arms within the pHS1 plasmid (figure 24).
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Figure 24. DNA Sequencing results of pHS1.
DNA sequencing results of the pHS1 plasmid from primer A.

DNA sequencing of the pHS1 plasmid as a negative control for gRNA
As expected, DNA sequencing of the purified pHS1 plasmid did not produce a DNA
sequence from primer F (figure 25) confirming the absence of the gRNA sequences within the
pHS1 plasmid.

Figure 25. DNA Sequencing of pHS1.
DNA Sequencing results of the pHS1 plasmid with Primer F.

3.3.

Construction of the pHS3 plasmid
Transforming E. coli with the pHS3 plasmid and screening

Following Golden Gate assembly of the gRNA into the pHS1 plasmid (pHS3), the
plasmid was transformed into E. coli via heat-shock. Isolated colonies that putatively contained
the pHS3 plasmid were observed after overnight growth on an LB plate containing 50 µg/mL of
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kanamycin and no colonies were visualized on a negative control Golden Gate Assembly
reaction of linearized pHS1 plasmid without a gRNA insert (figure 26).

Figure 26. Image of E. coli containing the pHS3 plasmid.
Left plate- The negative control plate of vector only (pHS1) without gRNA insert yielded no colonies.
Right plate-Isolated colonies were observed on the LB plate containing the transformed cells with the pHS3 plasmid.

Three colonies from the right plate were screened by PCR using primers E and F to
confirm the presence of the gRNA within the pHS3 plasmid yielded bands of the expected size
of 500 bp (figure 27).

Figure 27. Gel Electrophoresis Image of Polymerase Chain Reactions to Screen for gRNA within the pHS3
plasmid.
L- 1 kb NEB ladder, 1- pHS3 sample #1 (expected size = 500 bp), 2- pHS3 sample #2 (expected size = 500
bp), 3- pHS3 sample #3 (expected size =500 bp), 4- pHS1 (negative control), 5- pCasSA (negative control), 6- water
(negative control).
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Confirmation of the repair arms and gRNA within the pHS3 plasmid
DNA sequencing results of the pHS3 plasmid with primers A (Appendix B) aligned with
the JB wild-type sequenced genome repair arms using BlastN sequence analysis confirming the
presence of the repair arms within the pHS3 plasmid (figure 28).

Figure 28. DNA Sequencing of pHS3.
DNA Sequencing of the pHS3 plasmid with primer A.

DNA sequencing results of the pHS3 plasmid with primer F (Appendix B) aligned with
the JB wild-type sequenced genome repair arms using BlastN sequence analysis confirming the
presence of the gRNA within the pHS3 plasmid (figure 29).
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Figure 29. DNA Sequencing of pHS3.
DNA Sequencing results of the pHS3 plasmid with primer F.

3.4.

Insertion of the pHS3 plasmid into S. aureus RN4220
Transforming pHS3 into S. aureus RN4220 and screening.

S. aureus RN4220 transformed with the pHS3 plasmid yielded isolated colonies that
putatively contained pHS3 on a TSA (supplemented with 25 % dextrose and 0.1 M CaCl2) plate
with 10 µg/mL of chloramphenicol. No colonies were observed on a TSA (supplemented with 25
% dextrose and 0.1 M CaCl2) plate with 10 µg/mL of chloramphenicol of wild-type S. aureus
RN4220 (negative control) (figure 30).

43

Figure 30. Image of TSA plates (10 µg/mL chloramphenicol) containing isolated S. aureus RN4220 colonies
containing the pHS3 plasmid.
Left plate- No colonies were observed on the negative control plate of S. aureus RN4220.
Right plate- Isolated colonies of S. aureus RN4220 putatively containing the pHS3 plasmid were observed.

Polymerase chain reactions to screen for the presence of the pHS3 plasmid using primers
A and D within the S. aureus RN4220 colonies yielded bands of the expected size (1,877 bp) on
gel electrophoresis for at least 8/20 selected colonies indicating the presence of the pHS3
plasmid within S. aureus RN4220 (figure 31, lanes 1, 2, 3, 11, 13, 14, 18 and 20).

* * *

*

*

* *

*
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L-

Figure 31. Gel Electrophoresis Image of Polymerase Chain Reactions to Screen for the presence of pHS3
within S. aureus RN4220.
GeneRuler 1 kb Plus DNA Ladder, 1-20 picked colonies after electroporation of pHS3 into S. aureus RN4220
(expected size = 1,877), 21- purified pHS3 plasmid, positive control (expected size= 1,877), 22- picked colony of S.
aureus RN4220, negative control, 23- water, negative control. *- positive PCR amplicon.

3.5.

Infection of S. aureus RN4220-pHS3 with bacteriophage JB
Liquid Infection of S. aureus RN4220-pHS3 with bacteriophage JB

Liquid culture infection (10 uL) of JB in S. aureus RN4220-pHS3 and S. aureus RN4220
were observed after the two-day incubation period. The S. aureus RN4220-pHS3 cultures after
JB liquid infection appeared
* clear and after centrifugation (2,000 rpm for 5 minutes) no bacterial
pellet was observed (figure 27). The absence of bacterial growth from S. aureus RN4220-pHS3
culture after JB liquid infection suggested the presence of deletion mutant JB (JB30-33) with
strictly lytic capabilities. The S. aureus RN4220 culture after JB liquid infection appeared cloudy
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and after centrifugation (2,000 rpm for 5 minutes) a bacterial pellet was observed (figure 32).
The presence of bacterial growth from S. aureus RN4220 culture after JB liquid infection
suggests the formation of lysogens, which was expected due to wild-type JB’s lysogenic
capabilities.

Figure 32. Liquid infection of JB in S. aureus RN4220-pHS3 and S. aureus RN4220.
The image shows the difference in bacterial growth after JB infection of S. aureus RN4220 (left culture) compared
to S. aureus RN4220-pHS3 (right culture).

Plaque assay of S. aureus ATCC 33742 (PS88) with bacteriophage JB
and putative deletion mutant JB30-33.
After incubation, the resultant plaques from wild-type JB on S. aureus ATCC 33742
(PS88) appeared small and turbid/cloudy, which is indicative of a temperate bacteriophage. In
contrast, the resultant plaques from lysate of putative deletion mutant JB30-33 on S. aureus
ATCC 33742 (PS88) appeared small and clear, which is indicative of a lytic bacteriophage
(figure 33), suggesting deletion of genes 30-33 and JB’s ability to form lysogens.
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a.

b.

Figure 33. Plaque assay infections on S. aureus ATCC 33742 (PS88).
a.) Resultant plaques from putative deletion mutant JB30-33. b.) Resultant plaques from wild-type JB.

3.1.

Confirmation of deletion mutant JB30-33
Screening plaques for deletion mutant JB30-33 by PCR

Polymerase chain reactions were used to screen for the presence or absence of genes 3033 within the JB phage genome yielded the expected results (figure 34). The plaque from the
putative deletion mutant JB30-33 yielded a band of approximately 2,000 bp, indicating the
deletion of genes 30-33 (figure 34). Plaques from the wild-type JB phage yielded a band of
approximately 5,000 bp, indicating the presence of genes 30-33 (figure 34). The purified pHS3
as a positive control plasmid yielded a band of approximately 2,000 bp (figure 34). The negative
controls of an isolated colony from S. aureus ATCC 33742 (PS88) and sterile nuclease-free
water yielded no bands (figure 34).
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Figure 34. Gel electrophoresis image of Polymerase Chain Reactions to screen for the presence or absence of
genes 30-33 in phage plaques.
L-GeneRuler 1 kb Plus DNA Ladder, 1- putative deletion mutant JB30-33 plaque, 2-4 wildtype JB plaque, 5- pHS3 purified
plasmid, 6-PS88 colony, 7- water.

DNA sequencing of PCR product from wild-type JB and JB30-33.
DNA sequencing results of wildtype JB (5,000 bp) product with primer A (Appendix B)
aligned with the JB wildtype sequenced genome using BlastN sequence analysis (figure 35).

Figure 35. DNA sequencing results of wildtype JB (5,000 bp) PCR product.
DNA sequencing of the wildtype JB (5,000 bp) PCR product from primer A aligned with the full genome JB
sequence using BlastN sequence analysis.

DNA sequencing results of wildtype JB (5,000 bp) product with primer F (Appendix B) aligned
with the JB wildtype sequenced genome using BlastN sequence analysis (figure 36).
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Figure 36. DNA sequencing results of wildtype JB (5,000 bp) PCR product.
DNA sequencing of the wildtype JB (5,000 bp) PCR product from primer F aligned with the full genome
JB sequence using BlastN sequence analysis.

DNA sequencing results of deletion mutant JB30-33 product with primer A (Appendix
B) aligned with the JB wildtype sequenced genome using BlastN sequence analysis confirming
the presence of the repair arms (figure 37).

Figure 37. DNA sequencing results of JB30-33 (2,000 bp) PCR product.
DNA sequencing of the JB30-33 (2,000 bp) PCR product aligned with the full genome JB sequence using
BlastN sequence analysis.
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DNA sequencing results of deletion mutant JB30-33 product with primer F (Appendix B) did
not produce a DNA sequence confirming the absence of genes 30-33 (figure 38).

Figure 38. DNA sequencing results of JB30-33 (2,000 bp) PCR product.
DNA sequencing of the JB30-33 (2,000 bp) PCR product did not produce a DNA sequence.
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4. Conclusion
Staphylococcal bacteriophage JB, isolated from dairy cow hair samples, has the ability to
infect methicillin-resistant Staphylococcus aureus (MRSA). After genome annotation,
bacteriophage JB was determined to be a temperate phage that contains putative toxin and
integrase genes. In order to use JB as a potential phage for mammalian organisms, deletion of the
toxin and integrase coding genes is essential to produce a safe strictly lytic phage.
This study used a commercially available CRISPR/Cas9 expression plasmid, pCasSA, to
generate the pHS3 plasmid. The pHS3 plasmid contains a gRNA, a sequence specific to a cut site
within the genes of interest upstream of a PAM sequence to guide the Cas enzyme to the genes
30-33 within the JB genome. The pHS3 plasmid also contained 1,000 bp sequences flanking the
genes of interest (repair arms) to mediate homologous recombination after the Cas enzyme’s
double-stranded break of the JB genome, effectively removing genes the toxin and integrase
genes. The creation of the pHS3 plasmid with the repair arms and gRNA was confirmed by PCR
and DNA Sequencing.
Transformation of the pHS3 plasmid into S. aureus RN4220 generated S. aureus
RN4220-pHS3 which was subsequently infected with the JB bacteriophage. Liquid infection of
JB in S. aureus RN4220-pHS3 generated the deletion mutant JB30-33. Plaque assays of
JB30-33 on S. aureus PS88 showed a clear plaque morphology indicating a lytic bacteriophage,
in contrast to wildtype JB turbid plaque morphology indicating a temperate bacteriophage. The
creation of deletion mutant JB30-33 was confirmed by PCR and DNA Sequencing.
The genetically engineered derivative of JB phage, JB30-33, had the problematic
integrase and toxin genes removed for safety and demonstrated lytic capabilities in liquid
infections and plaque assays. Further characterization of JB30-33 is necessary to determine if
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JB30-33 host range on clinical isolate strains of S. aureus has altered infectivity compared to
wildtype JB. Future studies of JB30-33 and wildtype JB can be performed in vitro on cell
cultures and in vivo on murine organisms infected with S. aureus to determine its safety and
efficacy in phage therapy. Further characterization of JB30-33 can be performed by imaging
JB30-33 by transmission electron microscopy.
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5. Appendix A: Repair Arms and gRNA isolated from the JB genome.
Left Repair Arm:
5’CTGCAGTAGAGCAAAGTACGTTAGAAAAACAAAAAGAAAGATTGCACTTTCAAGA
TAATATTAAAAAAGCACATAAAAAAGTATATCGTGAATTTGTTAGTAAACAAAATA
AAGATAAAAAGGGGAAGGATAAATGATGTTTATAACTGGAATAGTGATATCGTTAG
TTGTAATCTTGATAGCTTCATATTTTTCCTTTGTTTTAACAACATTAATTATAAGCGA
AGATTTTAGTGACCGAGTTACTTTAAAAGTAGCATTTATCTTACCAATAATATTAAT
ATCCCTATCCATTCGTGCATGTTTAGAAAACCTAAGGAGTAATAAACAACTTGCTAA
AACAGCATTTAAAATGGCTACTACACAATATCCTTCAGTGGTAACAATGTTCATAGG
TATGGTTAAAGACCATCAAGCACAAGTCCACTGTTTTGGTGAATCTACCTATACCTA
TAACCAAAATAAAGAAAACCTAATATTAAAAAAAGACATAAATAAGTCATGGTTAA
ATTCATTAAAGAATTTGAAGTCACTTATTAAATCAGAAGGATTTAAAAAGAATTTTT
TAAATAACTTAGCTGAAGCTTAAGTTCTCGTATTACCTTCGATGATTATGAATTTTGC
TCAGCATGTAAAACCACACCACCTATTAATTTAGGAGTGTGGTTATTTTAATATATG
AAGCTAAAATAACTACAAATGATACCATTTTTGATACCATTTTGTTGTAAAACAGAA
AAAATAAGGAAAATAAAAAAGGCAAAAAAACGCATTAAATCAACGTTTATTGTCTC
ATGAAATTTAAATGTATATAAATTTCACTTCCCATGGGTCATTATGAATTCTTATTTT
AGGCTTGTTATTAC 3’
Right Repair Arm:
5’GTTTACTTTATGTGTTGACACTTTACTTTTAGTGTAGTAAATTAGATGCATACCTTA
CAAGGAGGTGACAACATGACAGATACAATTGAGGCATTTTCTCTAAAGGGTGCGCG
AAATGAATTTGATTACACGCAAGAGCAAATAGCTGATAAATTAGGGGTTTCTCGAG
CACAGTATATTGCGTGGGAAAAAGGTGATGTAATACCTAAAAGCATGGTAGTTTAT
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GCTTTAGCTTACATCTATGGTATTAACGCTGACTTATTAAGAGTCAGCAAAAAAATT
TAAAACTAACTTCACTTAAAGTGAAGTTGTGTAAAAACACGACAAAAGAAAAACAA
ACTATTTAAAAGGAGGAACTCAGATGCAAGCATTACAAACATTTAATTTTGAAGAAT
TACCAGTAAGAACATTAACAGTAAATGAGGAACCGTATTTTGTAGGGAAAGATGTA
GCAGATATTCTAGGTTACAAAAATGGCAGTCGTGATATTAACGCTCATGTTGATGCA
GAAGATAAGCTGACGTACCAAATCAGTACCGCAGGTCAAAGACGAAATCAAACAAT
CATCAACGAATCGGGTTTATACAGCCTAATCTTCTCATCAAAACTAGAATCAGCTAA
ACGATTCAAACGTTGGGTAACTTCAGACGTCCTACCCGCTATTCGAAAACACGGTAT
CTACGCAACAGACAATGTAATTGAACAAACATTAAAAGATCCAGACTACATCATTA
CAGTGTTGACTGAGTATAAGAAAGAAAAAGAGCAAAACTTACTTTTACAACAAGAA
ATTGGAGAGCTAAAACCCAAAGCAGACTATGTAGATGAAATCTTAAAGTCAACTGG
AACATTAGCTACAACTCAAATCGCGGCAGACTACGGTATATCAGCACAAAAGTTAA
ACAAACTACTACACGAAGCTAGATTACAACGAAAAGTGAATAAACAGT 3’
gRNA:
5’ CAAAGCTTCTACAATTTCGCGTAATGG 3’
3’CGAAGATGTTAAAGCGCATTACCGAAA 5’
*underlined PAM sequence
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6. Appendix B: Primers
6.1.

Table I
Melting
Primer Sequence

G/C

Primer Name

Temperature
(5’to 3’)

Content
(Tm)

A

GATCTGTCCATACCCATGG

(Left Repair Arm

TCTGCAGTAGAGCAAAGT

Forward)

AC
B

TGTCAACACATAAAGTAA

(Left Repair Arm

ACGTAATAACAAGCCTAA

Reverse)

AATAAGAATTCATAATGA

64.8oC

48.7 %

62.5oC

62.5 %

55.4oC

29.4 %

60.7oC

28.6 %

54.5oC

42.9 %

53.9oC

43.5 %

CC
C
(Right Repair Arm

GTTTACTTTATGTGTTGAC
AC TTTACTTTTAGTG

Forward)
D

AAGATACAGGTATATTTTT

(Right Repair Arm

CTGACTGTTTATTCACTTT

Reverse)

TCGTTGTAATC
E

(Confirm guide)
F
(Forward gRNA)

GATTCACCAAAACAGTGG
ACT
CAAAGCTTCTACAATTTCG
CGTAATGG
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G
(Reverse gRNA)

CGAAGATGTTAAAGCGCA

54.1oC

TTACCGAAA

*underlined sequences are homologous to pCasSA cloning sites

43.5 %
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7. Appendix C: Media
Tryptic Soy

To 1 L of sterile ddH20, 30 g Tryptic Soy Broth (Sigma-Aldrich) were added.

Broth ++

The solution was stirred until fully dissolved and heated until it came to a

(TSB ++)

boil. The solution was autoclaved on a liquid cycle for 20 minutes. Prior to
use, 25 mL/L of a 25 % sterile solution of dextrose and 10mL/L of a sterile
0.1 M CaCl2 solution was added. TSB ++ was stored in 4oC.

Tryptic Soy

To 1 L of sterile ddH20, 40 g Tryptic Soy Agar (Sigma-Aldrich) were added.

Agar ++

The solution was stirred until fully dissolved and heated until it came to a

(TSA ++)

boil. The solution was autoclaved on a liquid cycle for 20 minutes. Once the
solution was cool to the touch, 25 mL/L of a 25 % sterile solution of dextrose
and 10mL/L of a 0.1 M CaCl2 sterile solution were added. The mixture was
poured directly into Petri dishes and stored in 4oC or stored in a sterile
container at room temperature.

Top Agar ++

A 1:1 solution of TSA++: TSB++ is combined and the mixture is kept molten

(TSTA++)

at 65oC or stored at room temperature.

CaCl2 (0.1 M)

1.47 g of Calcium chloride was added to 100 mL of ddH20 and stirred until
fully dissolved. The solution was autoclaved on a liquid cycle for 20 minutes.

